Search results for "non-hodgkin"

showing 10 items of 116 documents

Incidence of childhood cancer of the head and neck in Germany.

2007

Background: Only very limited data are available in the literature on the incidence of childhood cancer of the head and neck worldwide. Methods: Based on data obtained from the national German Childhood Cancer Registry, a total of 370 malignancies of the head and neck in children under the age of 15 (199 boys and 171 girls), which were reported to this institution between 1994 and 2003, were analysed in this study. Results: The overall incidence of malignancies of specific sites of the head and neck in Germany is 4.48 per 100000 children. The most frequently observed entities, representing primary tumours, are soft tissue sarcomas (0.39/100000), lymphomas (0.09/100000) and thyroid carcinoma…

MalePediatricsmedicine.medical_specialtyAdolescentNeuroblastomaGermanyEpidemiologymedicineHumansThyroid NeoplasmsChildChildhood Cancer Registrybusiness.industryIncidence (epidemiology)IncidenceLymphoma Non-HodgkinHead and neck cancerInfant NewbornCancerInfantNasopharyngeal NeoplasmsSarcomaHematologymedicine.diseaseSurgeryParanasal sinusesmedicine.anatomical_structureOncologyEl NiñoHead and Neck NeoplasmsTonsilChild PreschoolFemalebusinessAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Single-dose Palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving mode…

2011

PURPOSE: The control of nausea and vomiting induced by chemotherapy is paramount for overall treatment success in cancer patients. Antiemetic therapy during chemotherapy in lymphoma patients generally consists of anti-serotoninergic drugs and dexamethasone. The aim of this trial was to evaluate the efficacy of a single dose of palonosetron, a second-generation serotonin type 3 (5-HT(3)) receptor antagonist, in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy (MEC) containing steroids. METHODS: Patients received a single intravenous bolus of palonosetron (0.25 mg) before administration of chemotherapy. Complete response (CR) defined as no vomiting …

MaleQuinuclidinesmedicine.medical_treatmentCINVCHOPGastroenterologyDexamethasoneSettore MED/15 - Malattie Del SangueAntineoplastic Combined Chemotherapy ProtocolsSerotonin 5-HT3 Receptor AntagonistsProspective StudiesAged 80 and overLymphoma Non-HodgkinPalonosetronNauseaMiddle AgedEmesisPalonosetronTreatment OutcomeOncologyAnesthesiaCHOP CINV Emesis Nausea NHL PalonosetronVomitingFemaleOriginal Articlemedicine.symptomCHOP-CINV; emesis; nausea; NHL; Palonosetronmedicine.drugAdultmedicine.medical_specialtyVomitingNauseamedicine.drug_classNHLYoung AdultInternal medicinemedicineHumansAntiemeticGlucocorticoidsAgedChemotherapybusiness.industryIsoquinolinesmedicine.diseaseNon-Hodgkin's lymphomaAntiemeticsbusinessCHOPChemotherapy-induced nausea and vomiting
researchProduct

Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18.

2015

Summary The aim of this study was to elucidate more clearly the role of interleukin (IL)-18 in modulating the IL-22 pathway in primary Sjögren's syndrome (pSS) patients and in pSS-associated lymphomas. Minor salivary glands (MSGs) from patients with pSS and non-specific chronic sialoadenitis (nSCS), parotid glands biopsies from non-Hodgkin lymphomas (NHL) developed in pSS patients, were evaluated for IL-18, IL-22, IL-22 receptor 1 (IL-22R1), IL-22 binding protein (IL-22BP) and signal transducer and activator of transcription-3 (STAT-3) expression. MSGs IL-22R1-expressing cells were characterized by confocal microscopy and flow cytometry in pSS, nSCS and healthy controls. The effect of recom…

MaleSalivary Glandslaw.inventionInterleukin 22lawIL-22Immunology and AllergyMyeloid CellsIL-22R1Receptormedicine.diagnostic_testnon-Hodgkin lymphomaLymphoma Non-HodgkinInterleukin-17TranslationalInterleukin-18Lacrimal ApparatusInterleukinMiddle AgedHaematopoiesisSjogren's SyndromeIL-22BPRecombinant DNASjögren's syndromeInterleukin 18FemaleIL-18Signal TransductionAdultSTAT3 Transcription FactorImmunologyPrimary Cell CultureBiologyPeripheral blood mononuclear cellIL-18; IL-22; IL-22BP; IL-22R1; Sjögren's syndrome; non-Hodgkin lymphomaSialadenitisFlow cytometrystomatognathic systemmedicineHumansAgedInterleukinsMacrophagesReceptors InterleukinSettore MED/16 - Reumatologiastomatognathic diseasesGene Expression RegulationImmunologyLeukocytes MononuclearClinical and experimental immunology
researchProduct

Risk of childhood leukaemia and non-Hodgkin's lymphoma after parental occupational exposure to solvents and other agents: the SETIL Study

2013

AIM: In the context of the Italian Multicentric Epidemiological Study on Risk Factors for Childhood Leukaemia and Non-Hodgkin's Lymphoma (SETIL), the risk of childhood cancer was investigated in relation to parental occupational exposures. METHODS: All cases of childhood leukaemia and non-Hodgkin's lymphoma (NHL) in children aged 0-10 years were identified. Controls were chosen at random from the local population in each region. Parents were interviewed using a structured questionnaire. The collected data were blindly reviewed by expert industrial hygienists in order to estimate exposure to a list of agents. Statistical analyses were performed for each agent using unconditional multivariabl…

MaleToxicologyEconomicaPregnancyhemic and lymphatic diseasesEpidemiologyChildMultivariate Analysiparental exposureIncidenceLymphoma Non-HodgkinIncidence (epidemiology)Precursor Cell Lymphoblastic Leukemia-LymphomaOccupational exposureEpidemiologic StudieItalyMaternal ExposureChemical IndustryChild PreschoolPrenatal Exposure Delayed EffectsSolventPaternal ExposureFemaleSurvival AnalysiHYDROCARBONSCase-Control StudieRisk assessmentHumanmedicine.medical_specialtyLogistic ModelAdolescentSocio-culturaleContext (language use)Risk AssessmentPrenatal Exposure Delayed EffectHazardous SubstancesAge DistributionEnvironmental healthmedicineHumansSex DistributionSurvival analysisACUTE LYMPHOBLASTIC-LEUKEMIAbusiness.industryPublic Health Environmental and Occupational HealthCase-control studyAmbientalemedicine.diseaseSurvival AnalysisNon-Hodgkin's lymphomaEpidemiologic StudiesPaternal ExposureLogistic ModelssolventsHazardous SubstanceCase-Control StudiesMultivariate AnalysisbusinessOccupational and Environmental Medicine
researchProduct

Testicular lymphoblastic leukemia/lymphoma

1995

Acute lymphoblastic leukemia is by far the most frequent malignant disease in children. In all, 5% of the boys affected will develop testicular disease either at initial presentation or during the disease course or as the first site of relapse. Modern treatment regimens have reduced the occurrence of testicular relapses, which was more frequent in the 1970s. There is no place for preventive measures for early recognition of testicular leukemia; routine biopsies have been abandoned, and prophylactic irradiation is not justified. In gross overt disease, orchiectomy is justified (1) in cases of huge bulky testicular disease, (2) if unilateral disease is probable, and (3) if radiation of the te…

Maleendocrine systemPediatricsmedicine.medical_specialtybusiness.industryLymphoma Non-HodgkinUrologymedicine.medical_treatmentLymphoblastic lymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCombined Modality TherapyLymphomaSurgeryRadiation therapyTesticular LeukemiaTesticular diseaseLeukemiaTesticular NeoplasmsAcute lymphocytic leukemiamedicineHumansOrchiectomyChildbusinessWorld Journal of Urology
researchProduct

Cancer in the older person.

2005

Cancer in the older person is an increasingly common problem, due to the progressive prolongation of the life-expectancy of the Western population. This article reviews the mechanisms associating aging and cancer, age-related changes in cancer biology, assessment of the older person to estimate life-expectancy, treatment tolerance, and medical and social conditions that may interfere with cancer treatment, effectiveness of cancer prevention and cancer treatment in older individuals. A comprehensive geriatric assessment (CGA) is commonly used to predict life-expectancy and functional reserve and to unearth conditions that may jeopardize cancer prevention and treatment. In the interest of cos…

Malemedicine.medical_specialtyColorectal cancerPopulationPRIMARY-CARE PATIENTSPainDiseaseProstate cancerNeoplasmsMedicineHumansPain ManagementRadiology Nuclear Medicine and imagingNON-HODGKINS-LYMPHOMAIntensive care medicineeducationELDERLY-PATIENTSGeriatric AssessmentSURGICAL ADJUVANT BREASTPreventive healthcareAgededucation.field_of_studyCancer preventionbusiness.industryCOMPREHENSIVE GERIATRIC ASSESSMENTCancerGeneral MedicineRANDOMIZED CONTROLLED-TRIALCOLONY-STIMULATING FACTORmedicine.diseasePROSTATE-CANCERClinical trialOncologyCOOPERATIVE-ONCOLOGY-GROUPPhysical therapyDIFFUSE HISTIOCYTIC LYMPHOMAFemalebusinessCancer treatment reviews
researchProduct

Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from th…

2013

International audience; BACKGROUND: Lymphoma occurring in patients aged 90 or older is not uncommon, and its incidence is expected to increase over time. Management of these patients is difficult given their underlying fragility and the lack of information regarding this population. PATIENTS AND METHODS: We retrospectively analyzed 234 patients diagnosed with lymphoma at the age of 90 years or older (90+) between 1990 and 2012 to describe their characteristics, management, outcomes and prognostic factors. RESULTS: The median age was 92 years; 88% were B-cell lymphomas consisting mainly in diffuse large B-cell lymphoma. The median overall survival (OS) was 7.2 months (range, 0-92 months) for…

Malemedicine.medical_specialtyPalliative careSurvivalPopulation[SDV.CAN]Life Sciences [q-bio]/Cancerlymphoma[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/Cancerimmune system diseasesInternal medicinehemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHypoalbuminemiaeducationSerum Albumin030304 developmental biologyCause of deathRetrospective StudiesAged 80 and over0303 health scienceseducation.field_of_studypalliative carebusiness.industryIncidence (epidemiology)IncidenceLymphoma Non-HodgkinHematologymedicine.diseasePrognosisComorbidity3. Good healthLymphomaSurgeryaged 80 and overcomorbidityOncology030220 oncology & carcinogenesisFemaleLymphoma Large B-Cell DiffusebusinessDiffuse large B-cell lymphoma
researchProduct

Linfomas malignos primários nas glandulas salivares

2011

Primary malignant lymphomas in the salivary glands are relatively rare. Clinical presentation is not characteristic and the disease is often overlooked resulting in diagnosis and treatment delays. AIM: To stress the importance of the diagnostic process and combined management, we present a series of eight patients with malignant lymphoma of the parotid who were diagnosed only after surgery and managed with radiation and chemotherapy. METHODS: Retrospective series of patients with primary malignant lymphoma of the parotid gland managed with radiotherapy and diagnostic surgical partial resection. RESULTS: After treatment completion we achieved a loco-regional control rate of 87.5%. Toxicity w…

Malemedicine.medical_specialtyPathologyglândulas salivaresSettore MED/06 - Oncologia Medicamedicine.medical_treatmentsalivary glandsSettore MED/19 - Chirurgia PlasticalymphomaDiseaseradioterapiaSettore MED/29 - Chirurgia Maxillofaccialestomatognathic systemlymphoma parotid salivary gland non-Hodgkin surgeryHumansMedicineStage (cooking)linfomalinfoma não hodgkinradiotherapyneoplasias parotídeasAgedRetrospective StudiesAged 80 and overPharmacologyChemotherapybusiness.industryLymphoma Non-HodgkinRate controlMiddle AgedPartial resectionmedicine.diseaseCombined Modality Therapynon-hodgkinLymphomaParotid glandRadiation therapyparotid neoplasmsTreatment Outcomemedicine.anatomical_structureSettore MED/31 - OtorinolaringoiatriaFemaleRadiologybusiness
researchProduct

Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha-interferon treatment

2004

Primary hepatic lymphoma is a rare but well-defined lymphoma entity that often pursues an aggressive clinical course. Most cases have been described in hepatitis C virus (HCV)-related chronic liver disease patients. Although anthracycline-based chemotherapy has been reported to be highly effective, the best therapeutic strategy has not been defined yet. The prognosis is dismal especially in patients treated with chemotherapy alone or when an advanced liver disease is present. Herein, we describe a case of primary hepatic large B-cell non-Hodgkin’s lymphoma, in a patient with HCV chronic infection. After a minor response with eight cycles of CHOP chemotherapy, a complete and sustained remiss…

Malemedicine.medical_specialtyalpha-interferonHepatitis C virusAlpha interferonCHOPChronic liver diseasemedicine.disease_causeGastroenterologyLiver diseasehemic and lymphatic diseasesInternal medicineremission primary hepatic lymphomaAntineoplastic Combined Chemotherapy Protocolsmedicinevirus infectionHumansUltrasonographyHematologybusiness.industryLymphoma Non-HodgkinLiver NeoplasmsRemission InductionInterferon-alphaHematologyHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseLymphomaLong-lastingImmunologyLymphoma Large B-Cell Diffusehepatitis Cbusiness
researchProduct

Splenic marginal zone lymphoma: A prognostic model for clinical use

2006

The Integruppo Italiano Linfomi (IIL) carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in 309 patients. The 5-year cause-specific survival (CSS) rate was 76%. In univariate analysis, the parameters predictive of shorter CSS were hemoglobin levels below 12 g/dL (P < .001), albumin levels below 3.5 g/dL (P = .001), International Prognostic Index (IPI) scores of 2 to 3 (P < .001), lactate dehydrogenase (LDH) levels above normal (P < .001), age older than 60 years (P = .01), platelet counts below 100 000/μL (P = .04), HbsAg-positivity (P = .01), and no splenectomy at diagnosis (P = .006). Values that maintained a negative influence …

Malesplenic marginal zone lymphoma; prognostic factors; International Prognostic Index (IPI)VILLOUS LYMPHOCYTESHydro-LyaseB-CELLLongitudinal StudiePredictive Value of TestInternational Prognostic Index (IPI)BiochemistryGastroenterologyHemoglobinschemistry.chemical_compoundInternational Prognostic IndexRisk FactorsBONE-MARROW INFILTRATION; NON-HODGKINS-LYMPHOMA; C VIRUS-INFECTION; VILLOUS LYMPHOCYTES; B-CELLBONE-MARROW INFILTRATIONAge FactorLongitudinal StudiesMultivariate AnalysiAged 80 and overUnivariate analysisHematologyMortality rateAge FactorsHematologyMiddle AgedPrognosisSplenic NeoplasmSurvival RatePredictive value of testsHumanAdultmedicine.medical_specialtyLymphoma B-CellPrognosiImmunologysplenic marginal zone lymphomaDisease-Free SurvivalPredictive Value of TestsAlbuminsInternal medicineLactate dehydrogenaseAdult; Age Factors; Aged; Aged 80 and over; Albumins; Disease-Free Survival; Hemoglobins; Humans; Hydro-Lyases; Longitudinal Studies; Lymphoma B-Cell; Male; Middle Aged; Multivariate Analysis; Platelet Count; Predictive Value of Tests; Prognosis; Risk Factors; Splenic Neoplasms; Survival Rate; Models Theoretical; HematologymedicineHumansHemoglobinNON-HODGKINS-LYMPHOMASplenic marginal zone lymphomaSurvival rateHydro-LyasesAgedPlatelet Countbusiness.industrySplenic NeoplasmsAlbuminRisk Factorprognostic factorsCell BiologyModels Theoreticalmedicine.diseaseSurgerychemistryMultivariate AnalysisbusinessC VIRUS-INFECTION
researchProduct